GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Kontafarma China Holdings Ltd (HKSE:01312) » Definitions » EPS without NRI

Kontafarma China Holdings (HKSE:01312) EPS without NRI : HK$-0.01 (TTM As of Dec. 2023)


View and export this data going back to 2012. Start your Free Trial

What is Kontafarma China Holdings EPS without NRI?

Kontafarma China Holdings's earnings per share without non-recurring items for the six months ended in Dec. 2023 was HK$-0.01. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-0.01.

During the past 3 years, the average earnings per share (NRI) Growth Rate was -12.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for Kontafarma China Holdings's EPS without NRI or its related term are showing as below:

HKSE:01312' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -60.2   Med: -33.1   Max: 7.7
Current: -12.6

During the past 13 years, Kontafarma China Holdings's highest 3-Year average Earnings Per Share (NRI) Growth Rate was 7.70% per year. The lowest was -60.20% per year. And the median was -33.10% per year.

HKSE:01312's 3-Year EPS without NRI Growth Rate is ranked worse than
77.45% of 847 companies
in the Drug Manufacturers industry
Industry Median: 9.2 vs HKSE:01312: -12.60

Kontafarma China Holdings's EPS (Diluted) for the six months ended in Dec. 2023 was HK$-0.01. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-0.01.

Kontafarma China Holdings's EPS (Basic) for the six months ended in Dec. 2023 was HK$-0.01. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-0.01.


Kontafarma China Holdings EPS without NRI Historical Data

The historical data trend for Kontafarma China Holdings's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kontafarma China Holdings EPS without NRI Chart

Kontafarma China Holdings Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EPS without NRI
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.01 -0.01 -0.02 -0.01 -0.01

Kontafarma China Holdings Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
EPS without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.01 -0.01 - - -0.01

Competitive Comparison of Kontafarma China Holdings's EPS without NRI

For the Drug Manufacturers - Specialty & Generic subindustry, Kontafarma China Holdings's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kontafarma China Holdings's PE Ratio without NRI Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Kontafarma China Holdings's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where Kontafarma China Holdings's PE Ratio without NRI falls into.



Kontafarma China Holdings EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$-0.01

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Kontafarma China Holdings  (HKSE:01312) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Kontafarma China Holdings EPS without NRI Related Terms

Thank you for viewing the detailed overview of Kontafarma China Holdings's EPS without NRI provided by GuruFocus.com. Please click on the following links to see related term pages.


Kontafarma China Holdings (HKSE:01312) Business Description

Traded in Other Exchanges
N/A
Address
30 Harbour Road, Room 12A 09-20, 12th Floor, Sun Hung Kai Centre, Wanchai, Hong Kong, HKG
Kontafarma China Holdings Ltd is principally engaged in the manufacture and sale of prescription drugs including chemical drugs and traditional Chinese medicine in the PRC, and the operation of fitness centers, provision of fitness and health consulting services, and the operation of franchises. The operating segments include pharmaceutical business and Fitness business. Majority of its revenue derives from pharmaceutical business segment.
Executives
Ning Bo Bao Shui Qu San Jin Guo Tou Gu Quan Tou Zi Ji Jin He Huo Qi Ye You Xian He Huo 2201 Interest of corporation controlled by you
Shan Xi Jiao Tong Kong Gu Ji Tuan You Xian Gong Si 2201 Interest of corporation controlled by you
Shan Xi Jian She Tou Zi Ji Tuan You Xian Gong Si 2201 Interest of corporation controlled by you
Shan Xi Sheng Ren Min Zheng Fu Guo You Zi Chan Jian Du Guan Li Wei Yuan Hui 2201 Interest of corporation controlled by you
Shan Xi Sheng Gao Su Gong Lu Ji Tuan You Xian Ze Ren Gong Si 2201 Interest of corporation controlled by you
Shan Xi Sheng Guo You Zi Ben Yun Ying You Xian Gong Si Qian Cheng Shan Xi Sheng Guo You Zi Ben Tou Z 2201 Interest of corporation controlled by you
China Health Management Investment Limited 2101 Beneficial owner
Waranty Assets Management (hk) Limited 2201 Interest of corporation controlled by you
Shen Zhen Shi Hua Rong Tai Zi Chan Guan Li You Xian Gong Si 2201 Interest of corporation controlled by you
Resuccess Investments Limited
Thtf Energy-saving Holdings Limited

Kontafarma China Holdings (HKSE:01312) Headlines

No Headlines